A topical nitric oxide platform company
NOxy is advancing a patented topical delivery platform designed to generate nitric oxide at the point of care—supported by peer-reviewed science and clinical development.
The unmet need
Hard-to-heal wounds can involve overlapping challenges in perfusion, inflammation, microbial burden, and tissue repair. NOxy is studying whether a topical nitric oxide platform can address this complexity at the point of care.
“We don’t want to be in the business of treating chronic wounds. We want to be the people who heal chronic wounds.”
Thomas L. Olds Jr., Chairman
Mission & values
It is our mission to reverse the overwhelming cost and trauma resulting from the epidemic of chronic wounds affecting millions of people throughout the world each year. We believe our research and resulting innovations in nitric oxide-based wound care topicals will help start a transformational shift from wound management to wound healing, while helping to restore the health, well-being and quality of life of those who suffer from chronic and debilitating wounds.
We begin with the person living with the wound. Our work is intended to reduce pain, infection risk, repeated procedures, loss of mobility, and loss of independence—while helping people preserve or regain health, quality of life, and human dignity.
We conduct research with disciplined protocols, prespecified methods and outcomes, careful data collection, qualified clinical and scientific partners, and transparent analysis. We report each finding in the context of the methods that produced it.
The platform is designed with practical future use in mind, including the potential for at-home application by patients, family members, or caregivers—not only clinicians. Any use would depend on the product’s regulatory status, approved labeling, and the individual care plan.
The platform
The two-component system keeps reactive materials separate until use, then combines them as a topical foam that generates nitric oxide at application.
The reactive components remain apart until the moment of use.
The components meet and create a conforming topical foam.
The reaction generates nitric oxide directly at application.
Evidence
To our knowledge, NOxy’s program is the largest body of research focused on a topical nitric oxide approach in wounds. It spans peer-reviewed biological research, controlled laboratory and tissue models, clinical development, and a 400-patient propensity-matched real-world analysis—one of the largest published pressure-injury and pressure-ulcer studies in older adults.
Rhonda Sullivan; Zwelithini Mzwandile Tunyiswa; Windy Cole; Lisa Gould; Mervin Low · International Wound Journal 23(5):e70911
In this retrospective, propensity-matched analysis of 400 older adults in skilled nursing facilities, modeled 12-week healing was 63% with nitric oxide-delivering foam and 34% with matched standard of care. Posterior probabilities favored the foam for most stage-specific comparisons.
David A. Bell; C. Michael Miller; Rhonda Sullivan · Journal of Wound Care 33(12):912–925
This scientific review organizes published evidence for nitric oxide across four interrelated wound-healing domains: blood flow and signaling, inflammation and immune response, microbial burden and biofilm, and tissue repair and remodeling.
Company updates
In Podiatry Today, Dr. Windy Cole reviews nitric oxide biology and places NOxy’s published 400-patient pressure-ulcer analysis in clinical context, including its stage-specific findings and real-world study design.
Read moreThe peer-reviewed retrospective analysis matched 200 NODF-treated older adults with 200 historical standard-of-care controls and reported modeled 12-week healing of 63% and 34%, respectively.
Read moreSmartTRAK’s market outlook reviews the biological rationale for nitric oxide, the delivery challenge, clinical and commercial activity across the field, and NOxy’s development and intellectual-property position.
Read more
